Beyond Air Partners with Healthcare Links to Expand Access to LungFit® PH System Through Group Purchasing Organizations and Integrated Delivery Networks

Rhea-AI Summary

Beyond Air (NASDAQ: XAIR) has announced a strategic partnership with Healthcare Links to expand access to its LungFit® PH system through Group Purchasing Organizations (GPOs) and Integrated Delivery Networks (IDNs) across the United States. The LungFit® PH system is a groundbreaking inhaled nitric oxide (NO) generator and delivery system for treating persistent pulmonary hypertension of the newborn (PPHN) and other respiratory conditions.

This partnership aims to streamline the entry of Beyond Air's technology into healthcare systems, leveraging Healthcare Links' expertise in facilitating relationships with GPOs and IDNs. The LungFit® PH system generates NO on-demand from ambient air, eliminating cylinder storage needs and enhancing patient safety and operational efficiency. The collaboration is expected to fast-track the availability of LungFit PH to a larger network of hospitals and healthcare providers, potentially benefiting more patients, particularly vulnerable newborns.

Positive

• Strategic partnership with Healthcare Links to expand access to LungFit® PH system
• Potential for faster market penetration through GPOs and IDNs
• LungFit® PH system eliminates need for cylinder storage, improving safety and efficiency
• LungFit® PH is FDA-approved for commercial use in the U.S. for specific neonatal treatments

Negative

• None.

Insights

Medical Technology Analyst

The partnership between Beyond Air and Healthcare Links represents a significant strategic move to expand market access for the LungFit® PH system. This collaboration has the potential to accelerate adoption rates by leveraging Healthcare Links' established relationships with GPOs and IDNs. The LungFit® PH system's innovative on-demand NO generation addresses key pain points in current NO delivery methods, offering improved safety and operational efficiency.

For investors, this partnership could translate to:

• Faster market penetration and revenue growth
• Reduced sales cycle and customer acquisition costs
• Potential for increased market share in the NO therapy space

However, it's important to note that while this partnership enhances distribution channels, actual sales growth will depend on factors such as pricing, reimbursement policies and competition. The 14 million market cap suggests Beyond Air is still in its early commercial stages, making this partnership important for scaling operations and potentially improving its financial position.

Healthcare Industry Consultant

This partnership signifies a strategic shift in Beyond Air's commercialization approach, potentially addressing key barriers to adoption for the LungFit® PH system. By leveraging Healthcare Links' expertise in navigating GPO and IDN landscapes, Beyond Air could significantly reduce the complexity and time involved in hospital procurement processes.

Key implications for the healthcare ecosystem include:

• Improved access to advanced NO therapy for neonatal care
• Potential cost savings for hospitals through streamlined logistics and storage
• Enhanced patient safety due to on-demand NO generation

For Beyond Air, this move could accelerate market penetration, but success will hinge on demonstrating clear clinical and economic benefits to healthcare providers. The partnership may also signal Beyond Air's readiness to scale, which could attract investor attention and potentially support future funding rounds or partnerships.

Revolutionary inhaled nitric oxide technology set to reach broader healthcare systems

GARDEN CITY, N.Y., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of endogenous and exogenous nitric oxide (NO) to improve the lives of patients, today announced entering a strategic partnership with Healthcare Links, a renowned healthcare advisory and contracting firm. This partnership is focused on expanding access to Beyond Air's LungFit^® PH system by streamlining entry into Group Purchasing Organizations (GPOs) and Integrated Delivery Networks (IDNs) across the United States.

Ken Murawski, President and Founder of Healthcare Links, commented, "We are thrilled to work with Beyond Air in introducing the LungFit PH system to our extensive network of progressive GPOs and IDNs. This technology not only enhances patient care but also significantly improves logistical efficiency for healthcare providers. It’s a game-changer, and we are eager to support its expansion across the healthcare continuum."

The LungFit^® PH system, a groundbreaking inhaled nitric oxide (NO) generator and delivery system, has been developed to treat patients with persistent pulmonary hypertension of the newborn (PPHN) and other associated respiratory conditions. The innovative technology allows for on-demand NO generation from ambient air, eliminating the need for cylinder storage, enhancing patient safety, and improving operational efficiencies for healthcare facilities.

With Healthcare Links’ expertise in facilitating relationships and contracts with GPOs and IDNs, this partnership will help fast-track the availability of LungFit PH to a larger network of hospitals and healthcare providers. By tapping into these critical distribution channels, Beyond Air aims to broaden the reach of its life-saving technology, ensuring that more patients, particularly vulnerable newborns, can benefit from this cutting-edge respiratory therapy.

"Our partnership with Healthcare Links marks a pivotal moment in our mission to make the LungFit PH system widely accessible to hospitals. We are confident that by leveraging Healthcare Links’ extensive knowledge of GPOs and IDNs, we will be able to more rapidly scale access for hospitals to our innovative NO delivery technology, addressing a critical need in respiratory care,” commented Steve Lisi, Chairman and Chief Executive Officer of Beyond Air.

The LungFit^® PH system is approved for commercial use in the U.S. to treat term and near-term neonates with hypoxic respiratory failure. Through this partnership, Beyond Air and Healthcare Links are committed to reducing barriers to entry and simplifying the contracting process, ensuring that hospitals across the country can seamlessly integrate this advanced respiratory therapy into their patient care protocols.

As Beyond Air continues to innovate in the field of respiratory medicine, this collaboration represents a significant step in the company’s mission to deliver life-saving solutions to those who need them most.

About LungFit^®*

Beyond Air’s LungFit is a cylinder-free, phasic flow generator and delivery system and has been designated as a medical device by the U.S. Food and Drug Administration (FDA). The ventilator compatible version of the device can generate NO from ambient air on demand for delivery to the lungs at concentrations ranging from 1 ppm to 80 ppm. The LungFit system could potentially replace large, high-pressure NO cylinders providing significant advantages in the hospital setting, including greatly reducing inventory and storage requirements, improving overall safety with the elimination of NO2 purging steps, and other benefits. LungFit can also deliver NO at concentrations at or above 80 ppm for potentially treating severe acute lung infections in the hospital setting (e.g. COVID-19, bronchiolitis) and chronic, refractory lung infections in the home setting (e.g. NTM). With the elimination of cylinders, Beyond Air intends to offer NO treatment in the home setting.

^{* Beyond Air’s LungFit PH is approved for commercial use only in the United States of America to treat term and near-term neonates with hypoxic respiratory failure. Beyond Air’s other LungFit systems are not approved for commercial use and are for investigational use only. Beyond Air is not suggesting NO use over 80 ppm or use at home.}

About Nitric Oxide

Nitric Oxide is a powerful molecule, naturally synthesized in the human body, proven to play a critical role in a broad array of biological functions. In the airways, NO targets the vascular smooth muscle cells that surround the small resistance arteries in the lungs. Currently, exogenous inhaled NO is used in adult respiratory distress syndrome, post certain cardiac surgeries and persistent pulmonary hypertension of the newborn to treat hypoxemia. Additionally, NO is believed to play a key role in the innate immune system and in vitro studies suggest that NO possesses anti-microbial activity not only against common bacteria, including both gram-positive and gram-negative, but also against other diverse pathogens, including mycobacteria, viruses, fungi, yeast and parasites, and has the potential to eliminate multi-drug resistant strains.

About Beyond Air, Inc.

Beyond Air, Inc. (NASDAQ: XAIR) is a global leader in medical technology focused on developing transformative treatments for lung diseases. The company’s LungFit^® platform is a revolutionary NO generation and delivery system aimed at treating a variety of respiratory conditions, from neonatal intensive care needs to adult respiratory distress. Beyond Air’s innovative, portable systems are designed to eliminate the need for NO storage and transportation, improving both patient safety and healthcare efficiency.

About Healthcare Links

Healthcare Links is a leading advisory and contracting firm that specializes in accelerating market access for healthcare products and services. With a vast network of GPOs, IDNs, and other healthcare purchasing entities, Healthcare Links provides manufacturers with critical insights and pathways to streamline market entry and enhance product distribution across the U.S. healthcare landscape.

For more information, please visit www.beyondair.net and www.healthcarelinks.net.

Forward Looking Statements

This press release contains “forward-looking statements” (as defined in Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended). You can identify such forward-looking statements by the words “appears,” “expects,” “plans,” “anticipates,” “believes” “expects,” “intends,” “looks,” “projects,” “goal,” “assumes,” “targets” and similar expressions and/or the use of future tense or conditional constructions (such as “will,” “may,” “could,” “should” and the like) and by the fact that these statements do not relate strictly to historical or current matters. Rather, forward-looking statements relate to anticipated or expected events, activities, trends or results as of the date they are made. Because forward-looking statements relate to matters that have not yet occurred, these statements are inherently subject to risks and uncertainties that could cause actual results to differ materially from any future results expressed or implied by the forward-looking statements. These forward-looking statements are only predictions and reflect views as of the date they are made with respect to future events and financial performance. Many factors could cause actual activities or results to differ materially from the activities and results anticipated in forward-looking statements, including those related to the completion of the offering, risks related to the ability to raise additional capital; the timing and results of future pre-clinical studies and clinical trials; the potential that regulatory authorities, including the FDA and comparable non-U.S. regulatory authorities, may not grant or may delay approval for our product candidates; the approach to discover and develop novel drugs, which is unproven and may never lead to efficacious or marketable products; the ability to fund and the results of further pre-clinical studies and clinical trials of our product candidates; obtaining, maintaining and protecting intellectual property utilized by products; obtaining regulatory approval for products; competition from others using similar technology and others developing products for similar uses; dependence on collaborators; and other risks, which may, in part, be identified and described in the “Risk Factors” section of Beyond Air’s most recent Annual Report on Form 10-K and other of its filings with the Securities and Exchange Commission, all of which are available on Beyond Air’s website. Beyond Air undertakes no obligation to update, and have no policy of updating or revising, these forward-looking statements, except as required by applicable law.

CONTACTS:
Investor Relations contacts
Corey Davis, Ph.D.
LifeSci Advisors, LLC
Cdavis@lifesciadvisors.com
P: (212) 915-2577

FAQ

What is the purpose of Beyond Air's partnership with Healthcare Links?

The partnership aims to expand access to Beyond Air's LungFit® PH system by streamlining entry into Group Purchasing Organizations (GPOs) and Integrated Delivery Networks (IDNs) across the United States.

What conditions does the LungFit® PH system treat?

The LungFit® PH system is designed to treat persistent pulmonary hypertension of the newborn (PPHN) and other associated respiratory conditions.

How does the LungFit® PH system generate nitric oxide?

The LungFit® PH system generates nitric oxide (NO) on-demand from ambient air, eliminating the need for cylinder storage.

Is the LungFit® PH system approved for use in the United States?

Yes, the LungFit® PH system is approved for commercial use in the U.S. to treat term and near-term neonates with hypoxic respiratory failure.